As a specific antagonist of chemokine receptor CXCR4, AMD3100 has been approved in human clinical trials for hematopoietic stem cell mobilization to the peripheral blood in patients with non-Hodgkin’s lymphoma and multiple myeloma[55,56]. This evidence concerns the gene CXCR4 and non-Hodgkin lymphoma.